- Home
- OB vs CLLS Comparison
OB vs CLLS Comparison
Compare OB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- CLLS
- Stock Information
- Founded
- OB 2006
- CLLS 1999
- Country
- OB United States
- CLLS France
- Employees
- OB N/A
- CLLS N/A
- Industry
- OB Industrial Machinery/Components
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- OB Industrials
- CLLS Health Care
- Exchange
- OB Nasdaq
- CLLS Nasdaq
- Market Cap
- OB 269.6M
- CLLS 240.2M
- IPO Year
- OB 2021
- CLLS 2007
- Fundamental
- Price
- OB $7.36
- CLLS $1.57
- Analyst Decision
- OB Buy
- CLLS Buy
- Analyst Count
- OB 5
- CLLS 3
- Target Price
- OB $6.10
- CLLS $7.00
- AVG Volume (30 Days)
- OB 358.8K
- CLLS 59.8K
- Earning Date
- OB 11-07-2024
- CLLS 11-04-2024
- Dividend Yield
- OB N/A
- CLLS N/A
- EPS Growth
- OB N/A
- CLLS N/A
- EPS
- OB N/A
- CLLS N/A
- Revenue
- OB $903,518,000.00
- CLLS $36,042,000.00
- Revenue This Year
- OB $0.80
- CLLS $271.02
- Revenue Next Year
- OB $8.13
- CLLS $33.48
- P/E Ratio
- OB $103.88
- CLLS N/A
- Revenue Growth
- OB N/A
- CLLS 46.96
- 52 Week Low
- OB $3.42
- CLLS $1.53
- 52 Week High
- OB $7.87
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- OB 68.30
- CLLS 27.91
- Support Level
- OB $6.26
- CLLS $1.85
- Resistance Level
- OB $7.87
- CLLS $2.09
- Average True Range (ATR)
- OB 0.44
- CLLS 0.09
- MACD
- OB 0.07
- CLLS -0.04
- Stochastic Oscillator
- OB 70.88
- CLLS 0.00
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.